The Mediterranean School of Oncology 56 th course Breast Cancer: from Epidemiology to Treatment Tunis, November 14, 2008
Consorzio Interuniversitario Nazionale per la Bio-Oncologia The Mediterranean School of Oncology An educational program of:
Bologna Chieti-Pescara Ferrara Catanzaro Palermo Roma La Sapienza Napoli Federico II Perugia Ancona Teramo LAquila A Consortium of 15 Italian Universities Foggia Messina Milano Campus Biomedico 32 Full Professors, 55 Associate Professors 95 Scientists 2 Clinical Trial Offices sqm laboratories 15 Cancer Clinics Tumor Registry & Screening Programs
Two classes: 1. Italian residents 2. Foreign students (in English); All courses are accredited for ECM by Ministero della Salute, Italy or/and ESMO
Courses/year Students/year By December 2007: 47 courses >2500 students
Italy Lithuania Jordan USA Turkey Egypt France Spain Iraq Bosnia Israel Russia Polland Students by country 1954 Belgium Germany Iran
Molecular pathology & cancer genetics Onco-hemathology Medical oncology Radiation oncology Epidemiology/ biostatistics & clinical trials Cancer prevention & early diagnosis ….. A large spectrum of cancer-related disciplines is covered, including:
Postgraduate courses; Training courses for health professionals not frequently dealing with cancer patients; Special topics for oncology nurses; Master classes (residential, 2-weeks, with practical workshops) ( Coming soon) Educational program
Scholarships Available to candidates <30 years of age. To apply for a scholarship: a brief curriculum vitae; a letter of presentation from an authorised officer at the institute of affiliation. For information:
Diapo avaible a partir du 24 novembre prochaine:
Bologna Chieti-Pescara Ferrara Catanzaro Palermo Roma La Sapienza Napoli Federico II Perugia Ancona Teramo LAquila A Consortium of 15 Italian Universities Foggia Messina Milano Campus Biomedico
2008 – Course calendar March 3-4*Digestive cancers: from epidemiology to management March Assessing and managing toxicities of molecularly targeted agents April Highlights in management of gastrointestinal cancer May 9-10Highlights in the management of prostate cancer June 13-14Highlights in the management of NSCL cancer July 4-5Highlights in the management of breast cancer September 26-27Highlights in management of kidney cancer October 16-18to be defined October 23-26to be defined November 7-8to be defined November 28-29Translational oncology: novel agents, approaches and targets *Cairo, Egypt
Consorzio Interuniversitario Nazionale per la Bio-Oncologia A MSO/CINBOs pilot project The Formazione a Distanza in Oncologia (FADO) Program
FADO Program Teaching is made via satellite technology. Designed to build or enhance professional knowledge, skills, and leadership in oncology and related disciplines through distance/online education & training.
Target audience 1. Residents in medical oncology; 2. Ph.D. students (Dottorato di Ricerca) in oncology and related disciplines Consorzio Interuniversitario Nazionale per la Bio-Oncologia
FADO - Partners Technologies & services: Organization & management:
Consorzio Interuniversitario Nazionale per la Bio-Oncologia A MSO/CINBOs pilot project The Mediterranean Task Force for Cancer Control (MTCC)
courses videoconferences; lectures-seminars-lessons; To provide a forum for distance learning discussion among CINBO member Universities and selected medical Institutions within the mediterranean area MTCC An innovative project to raise awareness about cancer prevention and early detection via satellite technology
Algeria Croatia EgyptFranceGreece Italy JordanLebanon LybiaMorocco Portugal SyriaSloveniaSpainTunisiaTurkey Palestine Launching Meeting of the Mediterranean Task Force for Cancer Prevention and Early Detection (MTCC) February 2nd, 2007 Rome, Italy With the participation of delegates from: Albania
Axel Ullrich Pioneer in signal transduction & cancer research Cloned human insulin gene licensed to Eli Lilly Discovered EGFR, HER2, FLK-1 etc Architect of targeted therapeutics One of the first scientists at Genentech Responsible for Herceptin – annual sales ca. >$1.0BN Discoveries led to SUTENT – projected sales >$1.0BN Director of Max Planck Society Founder of SUGEN Inc. NASDAQ listed in 1994 Sold to Pharmacia in 1997 for $670m